HTR2A and metabolic dysfunction-associated steatotic liver disease: In conclusion, we suggest that compound 11c is a promising drug candidate, which functions as a peripheral 5HT2A antagonist aiming for MASLD and liver fibrosis, which is in phase 1 clinical trial (NCT05517564)32.